
New Migraine Prevention Guidelines Highlight CGRP Therapies and Personalization
The American Academy of Neurology and the American Headache Society released updated migraine prevention guidelines that incorporate CGRP-targeted therapies and emphasize individualized treatment decisions based on efficacy, tolerability, long-term safety, and cost for episodic and chronic migraine. The guideline expands recommendations to more patients (those with frequent migraine days) and outlines preferred options (atogepant, CGRP monoclonal antibodies, and onabotulinumtoxinA, alongside older meds like propranolol, topiramate, and valproate). It also provides guidance on trial duration (8–12 weeks for most meds, 24 weeks for onabotulinumtoxinA), pregnancy considerations, comorbidities, medication overuse, and nonpharmacologic approaches to optimize care.




